Research programme: JNK inhibitors - CrystalGenomics
Latest Information Update: 31 May 2010
At a glance
- Originator CrystalGenomics
- Class
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammation; Neurological disorders